Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Hand Skin Is Additionally Significant - What You Ought to Realize About Hand Cream - 2The cheap health insurance promoted by Trump officials has this catch
- 3Vote In favor of Your Favored Occasion Arranging Administration
- 4Insane Realities That Will Make You Reconsider How you might interpret History
- 5An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- New York to require social media platforms to display mental health warnings
- The most effective method to Go with Informed Choices on Vehicle Leases
- 7 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
- Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
- The Way to Business: Startup Illustrations Learned
- What is IDF's view on pontential long-term occupation of southern Lebanon?
- Phenomenal Web-based MBA Stages for Proficient Headway
- Obamacare enrollment declines as US subsidies expire
- Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
